Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hear this occasionally...
NASDAQ Extension until March 7
Heads up, stay tuned.
Friday afternoon news dump? In May 2018, it took 4 business days after the NASDAQ hearing for IPCI to PR that they had received an extension. Today is day #6 after the hearing on 1/10/19.
Purdue already said thanks but no thanks
You are waiting for the wrong announcement...
Very, very well done.
Impressive and Robust
Still pumpy, but better.
It's all relative.
Nothing in either of your posts disputes the science of isradipine over all other CCB's for PD. Isradipine has the highest affinity for CaV1.3 relative to CaV1.2. All other CCBs, even those which cross the blood brain barrier and have some affinity for CaV1.3, are inferior to isradipine because of the higher affinity for CaV1.3 vs. CaV1.2. That means any other CCB is more likely to lower a patient's blood pressure, even if it is neuroprotective. That's why isradipine is the **ONLY** CCB to have a Phase 2 and Phase 3 study for Parkinson's Disease. And that's why isradipine will be the **ONLY** CCB that will be Rx'ed for PD.
Sorry, we all know this is incorrect.
Follow the shares.
In a way, yes...
Huh?
Think whatever you want.
Nonsense
Another interesting point about those lists...
https://www.lowestmed.com/top-100-drugs-lists/
Not only does ELTP own ANDA's for the top 3 drugs filled without insurance coverage, but also amlodipine is in the top 10 on both lists. I have a buttload of patients who take amlodipine for blood pressure, and if STEADYPD-III is positive, I will change a goodly number of those scripts to isradipine. I love using generic drugs that have multiple benefits, and in the next few months, we will hear if isradipine fits that description. Why would I continue to prescribe a calcium channel blocker that only decreases blood pressure when I could prescribe a different calcium channel blocker that lowers BP and also protects against neurological damage? The STEADY results are all I'm waiting for, and as soon as positive results are available, I will start prescribing it. I will not need to wait for FDA to say anything about it. I'll just start prescribing isradipine instead of amlodipine for BP, and I bet a lot of PCP's will eventually be doing the exact same thing.
Divy shares arrived at Schwab.
Both the brokerage and Rollover IRA accts went from 100 to 2100 shares. The share price went from 18.99 to .9043, the market value is unchanged at $1899, and both are designated to see footnote #6.